Key result
Adjuvant chemotherapy for poorly differentiated angiosarcoma of the breast resulted in a higher proportion of relapse-free patients compared to no adjuvant chemotherapy (29.2% vs 4.4%, p<0.05).
Why the study?
Does adjuvant chemotherapy improve relapse-free survival in patients with angiosarcoma of the breast?
Case Report
Does adjuvant chemotherapy improve relapse-free survival in patients with angiosarcoma of the breast?
Adjuvant chemotherapy may improve relapse-free survival in patients with poorly differentiated angiosarcoma of the breast, and long-term survival is possible even in metastatic disease.
Answers are grounded in this paper and cite their sources.
May support adjuvant chemotherapy in poorly differentiated breast angiosarcoma; hypothesis-generating and requires prospective validation before practice change.
Angiosarcoma of the breast is a rare and highly malignant neoplasm with few long-term survivors. Little is known about the effects of chemotherapy for patients with disseminated disease or its role in the adjuvant setting. We report the case of a patient with metastatic angiosarcoma of the breast who achieved a long-term clinical and pathological remission after treatment with methotrexate. The 30-year course of her disease is the longest reported survival with documented metastatic angiosarcoma of the breast. Analysis of the role of chemotherapy in the adjuvant setting and its effects in relation to histological subtype is undertaken. Adjuvant chemotherapy for patients with poorly differentiated angiosarcoma of the breast results in a higher proportion of patients relapse-free (29.2%) compared to patients not receiving adjuvant chemotherapy (4.4%) (p < 0.05). Patients with well-differentiated tumors do not appear to derive benefit from adjuvant chemotherapy. The effects for patients with disseminated disease are reported.
No takes yet. Share an insight, caveat, or question.
Silverman et al. (1994) conducted a case report in Angiosarcoma of the breast. Adjuvant chemotherapy vs. No adjuvant chemotherapy was evaluated on Relapse-free survival (for poorly differentiated angiosarcoma) (p=< 0.05). Adjuvant chemotherapy for poorly differentiated angiosarcoma of the breast resulted in a higher proportion of relapse-free patients compared to no adjuvant chemotherapy (29.2% vs 4.4%, p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: